Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

127.57 +0.06 (+0.05%)
Official Closing Price Updated: 4:10 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,551,347
Open 127.18
Bid (Size) 127.41 (1)
Ask (Size) 127.65 (1)
Prev. Close 127.51
Today's Range 126.76 - 127.73
52wk Range 99.14 - 133.10
Shares Outstanding 2,531,374,696
Dividend Yield 2.29%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
In a market where value is scarce, NYSE:MRK offers a refreshing opportunity with its solid fundamentals.
MERCK & CO. INC. (NYSE:MRK) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill

Performance

YTD
+12.65%
+12.65%
1 Month
-0.33%
-0.33%
3 Month
+1.10%
+1.10%
6 Month
+22.26%
+22.26%
1 Year
+7.76%
+7.76%

More News

Read More
Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
From Merck & Co., Inc.
Via Business Wire
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
Via Talk Markets
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Via Investor's Business Daily
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Merck (MRK) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Via Benzinga
S&P 500 Down Over 1%; Merck Increases 2024 Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Meta Falls 15% On Great Earnings, Tesla Rises 12% On Ugly Earnings – Here Is The Real Reason
Via Benzinga
Merck Rides Keytruda To Another Beat-And-Raise, But Diabetes Headwinds Persist
Via Investor's Business Daily
Merck Announces First-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Via Benzinga
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Via Benzinga
Investor Alert: Prepare for the Market Crash With These 3 Stocks
Via InvestorPlace
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.